Basilea Pharmaceutica Ltd., of Basel, Switzerland, reported that a phase III trial showed its antibiotic ceftobiprole to demonstrate more rapid clinical responses in hospital-acquired pneumonia and community-acquired pneumonia than a comparator regimen.